The Industry’s First and Only FDA-Inspected Direct-to-Patient Site
Our contribution to overall study enrollment is consistently among the highest across all participating sites. By expanding access beyond the typical 30-mile catchment area of traditional brick-and-mortar sites, we routinely deliver top-tier enrollment velocity.
Science 37 eliminates participation barriers by delivering clinical trials directly to patients' homes.
Explore how we can scale patient accessibility and streamline enrollment for your specific protocol.
Investigators licensed across all 50 states provide clinical trial access to 100% of the U.S. target population, driving seamless, diverse enrollment.
Streamlined Start-Up: One 1572, One Budget, and Central IRB Approvals
Study start-up times accelerated through comprehensive operational support.
Direct-to-Patient IMP Management
Investigational Medicinal Product (IMP) is shipped directly to the patient’s home 1–2 days before dosing with oversight from our Research-Grade Nurses maintaining a strict chain of custody, administration of IMP, and standardized temperature monitoring.
Centralized Kit Deployment
Logistical support provides management and oversight of clinical equipment and lab kits centrally, shipping them from our NC headquarters 1–2 weeks before a visit. Upon arrival, our Research-Grade Nurses verify delivery and prepare setup.
Specialized Research-Grade Nurses
An in-house network of 150+ multi-state licensed Research-Grade Nurse employees complete rigorous protocol-specific training, GCP/IATA certifications, and an Investigator-led clinical competency exam before conducting any visits.
Rigorous Investigator Oversight
Patient safety and data integrity remain our top priorities. Science 37 Investigators maintain strict oversight of visits via telemedicine, ensuring direct visualization of both the nurse and the participant. This enables real-time guidance of clinical assessments, immediate electronic data capture (eSource) review, and proactive adverse event management, mirroring or exceeding the rigor of a traditional site in a direct-to-patient model.
Disclaimer: The information presented reflects Science 37's experience and observations across studies utilizing its direct-to-patient clinical trial model. Certain performance metrics referenced herein are based on a retrospective analysis conducted jointly by Science 37 and the Tufts Center for the Study of Drug Development (Tufts CSDD) and should not be interpreted as guarantees of future performance or outcomes. Individual study results may vary significantly based on protocol design, therapeutic area, patient population, sponsor requirements, operational considerations, and other factors.
When Added Alongside Traditional Sites, Science 37 Can Improve Study Performance.
FDA Inspected
Enrolling 28% of Total Participants For a Phase 3 Asthma Study
Over a 15-month window, Science 37 enrolled the majority of the trial's patients, accelerating the overall time-to-target.
Enrolled
28%
of Total U.S. Study Participants
Science 37: 712 Patients 55 Traditional Sites Combined: 1,815 Patients
22x
Faster Enrollment Compared to Traditional Sites
Science 37 Avg. Patients/Month – 44 Single Traditional Site Avg. Patients/Month – 2
Top Enrolling Site
among 56 sites
See how this momentum scales across Hepatology, Cardiology, CNS, and other therapeutic areas.
